Vote NO on Proposition 71

The claim: Prop 71 will save money on health care costs

The supporters of Proposition 71 claim that the initiative will eventually save money on health care costs. This idea was made up out of thin air and is outright false. The reality is that embryonic stem cell treatments will cost more than conventional treatments. A recent cost analysis in the Proceedings of the National Academy of Science revealed that the cost would be of over $200,000 per patient!

"This analysis of the limited body of literature raises concerns about the feasibility and relevance of therapeutic cloning, in its current embodiment, for human clinical practice. A crucial difference is that, although 100 mouse oocytes can be obtained from a few superovulated females at a cost of [approximately] $20, human oocytes must be harvested from superovulated volunteers, who are reimbursed for their participation. Add to this the complexity of the clinical procedure, and the cost of a human oocyte is [approximately] $1,000-2,000 in the U.S. Thus, to generate a set of customized ntES (nuclear transfer embryonic stem) cell lines for an individual, the budget for the human oocyte material alone would be [approximately] $100,000-200,000. This is a prohibitively high sum that will impede the widespread application of this technology in its present form."1

Vote NO on Proposition 71

The claim: Prop 71 will provide Patent and Royalty Revenues to the state

Who will get the patent and royalty revenues from funded research? Proposition 71 does not require that one single penny of the patent and royalty revenues that might result from future research be returned to California taxpayers. The “Institute” established by Proposition 71 may, at its discretion, have taxpayers pay 100% of the costs, and award venture capitalists with 100% of the profits.

Vote NO on Proposition 71

The claim: Prop 71 will generate sales tax to cover the bond interest payments

Proponents of Prop 71 claim that sales tax generated by the proposition will cover the cost of the bonds. However, their own economic study indicates that this claim is false:

“New state income and sales taxes generated from the program will supposedly cover the interest due on the bonds during the first five years. But the supporters’ own economic study shows that in the following nine years, when annual debt service on the bonds soars to more than $170 million, the putative tax gains will cover only 11% to 19% of that sum.” Michael Hiltzik, Los Angeles Times, 8/23/04


  1. Mombaerts P. "Therapeutic cloning in the mouse." 2003. Proceedings of the National Academy of Science 100:11924-5.